Print Page   |   Contact Us   |   Sign In   |   Join
BioArbor - Steering Committee
Share |


 


 




Jack Ball

 

Jack Ball is the CEO and board member of Solulink, a San Diego biotech tools companies supplying technology that enables faster and quantitative conjugation of biomolecules with higher efficiencies and yields. He is president of Tyball Associates, LLC, a consulting company bringing 21st century sales and marketing strategies, that are highly capital efficient, to companies in the biotech tools space. He is an adjunct professor at the University of Michigan’s Ross Business School in Entrepreneurial Studies. In addition he serves on the board of directors of the following seven companies: 3D Biomatrix, Biophotonics, ENT Biotech Solutions, IntelliCyt, RealBio Technology, Swift Bioscience, and ViroCyt.

 

Email: Jack@tyball21.com




John Freshley

 

John Freshley currently serves as the president and CEO of ONL Therapeutics, an emerging ophthalmic therapeutics company. John has nearly two decades in leadership roles of fast-paced entrepreneurial companies within both the life science and software fields. His expertise spans the assembly of multi-disciplinary leadership teams, product and business strategy development, partnership development, communications, and venture capital fundraising. Prior to joining ONL, John was chief business officer of Compendia Bioscience through its acquisition by Life Technologies. He helped launch the company in 2006 with co-founders from the University of Michigan and served as its interim chief executive officer. Previously, John had been president and chief executive officer of Genetics Squared, an Ann Arbor start-up focused on developing personalized oncology drugs and diagnostics.

 

Email: jfreshley@onltherapeutics.com




David A. Gregorka  

 

Dave Gregorka is an operations executive who has been part of successful start-up teams for two new companies—one in science and technology and the other in health and technology. He helped to grow both to successful exits. In addition, he built and implemented a highly successful third-party drinking water materials standards testing and certification business for NSF International. Dave has raised over $20 million in venture capital and grants, and has expertise in new ventures leadership, fund raising, M&A, corporate administration, technology management, financial leadership, client services, and operations management. Currently, Dave is a Venture Partner for Baird Capital, representing the firm in Michigan. He also works as a Mentor-in-Residence at the University of Michigan’s Office of Technology Transfer. He is the principal in a consulting business that provides assistance to new and growing companies. He serves as the Chief Operating Officer for Jool Health, Inc. Dave holds a BS in Biology-Geology from the University of Rochester, an MS in Water Resources Management from the University of Michigan, and an MBA from the University of Michigan Ross School of Business.

 

Email: DGregorka@rwbaird.com




Mike Johnson

 

Mike is an Entrepreneur in Residence and Lecturer at the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan and a Mentor in Residence at the Venture Center at the University of Michigan. Mike is an entrepreneur and investor who has focused on companies that address big problems in life sciences, medical devices and health IT. Mike joined the University of Michigan from Flagship Ventures where he led the Midwest office for the venture capital firm with $1.4 billion in capital under management. Previously, Mike co-founded Converge Medical Technologies, an innovative neuromonitoring company and was a Medical Innovation Center Fellow at the University of Michigan. He holds MD and MBA degrees from the University of Michigan, where he was awarded the David T. Shelby Award for Leadership to the Fund, and a BA degree in English from Duke University.

 

Email: mljohnson@gmail.com




Brad Martin, PhD

 

Dr. Brad Martin is the commercial program director for MTRAC for Life Sciences, focusing on the development and commercialization of life science products and devices. He brings over 15 years of experience in the development of drugs and biologics. In his role, Brad utilizes his experience and knowledge of the biotech community to assists faculty in securing start-up funding, formulating realistic product development and business plans, and recruiting experienced management. Brad obtained his PhD in Physiology from the University of Michigan Medical School.

 

Email: bradmart@umich.edu




Tom Marten

 

Tom Marten is the Coulter Program Director at the University of Michigan. Tom has over 25 years of life science industry and consulting experience with significant experience in new product planning, commercial strategy development, licensing assessments, market research, sales, and brand marketing. Prior to joining U-M, Tom had leadership roles with Glaxo, Bayer Biological Products, and Talecris Biotherapeutics. After a 19-year career in pharma and biotech, Tom founded Pharmacision, an independent consulting firm where he spent seven years working with early stage specialty pharma and medical device companies guiding marketing, business strategy planning, investor fundraising, and out-licensing efforts. Tom has also served as COO for RetroSense, an early stage gene therapy company and as commercial strategy consultant for Aastrom Biosciences. Tom received a BS in Medicinal Chemistry from the State University of New York at Buffalo and an MBA in Finance from the William E. Simon School of Business at the University of Rochester.

 

Email: tmarten@umich.edu




Sarah Murchison

BioArbor Chairperson

 

Sarah Murchison currently serves as head of sales and marketing at New Perspectives, Inc., a privately held consulting firm in the emerging biotech and pharmaceutical industry. For the last 10 years, she has focused solely on emerging organizations with leadership responsibility for developing global commercialization assessments and strategies, new product planning, strategic and tactical launch plans, operational implementation, and lifecycle management strategies. Previously Sarah served as head of marketing for Eurand (acquired by Aptalis) and Adolor (acquired by Cubist) and began her industry career with Merck Human Health. She received her undergraduate degree from The College of Wooster and holds a Masters of Health Administration from Washington University School of Medicine.

 

Email: smurchison@newperspectives-us.com




David C. Olson, PhD

 

David Olson, PhD is a Mentor-In-Residence at the University of Michigan, and the former CEO of Swift Biosciences Inc. Dr. Olson has more than 18 years of experience in building life science companies, product development, intellectual property management, business development, and venture financing. He has co-founded six biotech start-ups, managed other early-stage businesses, and authored business plans backed by more than $61M in capital. Prior to Swift, Dr. Olson was a founding member of Accuri Cytometers Inc. (acquired by Becton Dickinson in 2011 for $205M), where he was responsible for creating Accuri’s product vision and played a central role in all aspects of corporate strategy, including financing and business development. Dr. Olson received his doctorate in Molecular Biology from Princeton University, and completed a postdoctoral fellowship at the University of California, San Francisco.

 

Email: olsonphd@gmail.com




Julia C. Owens, PhD

 

Dr. Julia Owens has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. She is currently President and CEO of Millendo Therapeutics, Inc., a clinical-stage therapeutics company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. Prior roles include senior vice president, corporate development and strategy at Lycera Corp., and head of business development at QuatRx Pharmaceuticals. Earlier in her career, Dr. Owens worked at Tularik Inc. (acquired by Amgen) and at the UCSF Office of Technology Management. Dr. Owens holds a PhD in Biochemistry from UCSF and a BS in Chemistry and BA in Molecular and Cellular Biology from UC Berkeley.

 

Email: owens@millendo.com




Mona Patel

 

Mona Patel is the vice president for clinical training and fellowship education for the Neuromodulation Division of Boston Scientific. In her role, she is responsible for the training and education of clinicians in the use of Boston Scientific spinal cord stimulator products. She previously served as the division’s vice president of marketing where she launched the first rechargeable spinal cord stimulator. Prior to joining Boston Scientific, Mona spent eight years in Guidant’s Cardiac Surgery Division. She was a key member of the team that introduced a novel procedure, endoscopic vessel harvesting, which now has become standard of care in cardiac surgery. She earned a BS in Mechanical Engineering from the University of Michigan and an MBA from the University of Pennsylvania, Wharton School of Business.

 

Email: Mona.Patel@bsci.com




Stephen Rapundalo, PhD

 

Dr. Rapundalo has broad experience in the life sciences, with an extensive background in pharmaceutical research and development. Prior to joining MichBio in April 2006 as the president and CEO, he spent almost 20 years as a senior research scientist, project manager, and group leader with Parke-Davis Pharmaceutical Research and then Pfizer, Inc., primarily in the area of cardiovascular drug discovery. Dr. Rapundalo has a superb record of scientific achievement with over 50 publications, book chapters, and monographs. He has served as a peer-reviewer for a variety of prominent scientific journals and national funding agencies. Dr. Rapundalo has been a community advocate and civic leader for almost 20 years and formerly served as an elected member of the City Council in Ann Arbor, Michigan.

 

Email: srapundalo@michbio.org




Braden Robison

 

Braden Robison has 15 years of experience in medical devices where he has held various operating roles ranging from product development, to sales and marketing, to M&A. With an engineering background, Braden has launched over one hundred products through the FDA regulated process and is named on eleven patents and applications. After completing his MBA, Braden continued to focus on cutting edge products and led due diligence on over 40 companies. He has successfully completed $235M worth of transactions and started two different divisions for Stryker Corp. Braden not only acquired businesses but operated them as well, driving both successful integration and profitability. Most recently he was responsible for strategy for Stryker’s largest brand ($1.5B WW). Braden currently works with the University of Michigan and a collection of startup/early stage companies to drive innovation to the device market.

 

Email: braden.robison@gmail.com

 

 

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership.com®  ::  Legal